

A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections

M. LI-NG¹, J. F. ALOIA^{1*}, S. POLLACK¹, B. A. CUNHA², M. MIKHAIL¹, J. YEH¹
AND N. BERBARI³

¹ Bone Mineral Research Center, ² Department of Infectious Diseases, ³ Department of Internal Medicine, Winthrop University Hospital, Mineola, NY, USA

(Accepted 11 February 2009; first published online 19 March 2009)

SUMMARY

Vitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during winter may cause increased susceptibility to upper respiratory tract infections (URIs). To determine whether vitamin D supplementation during the winter season prevents or decreases URI symptoms, 162 adults were randomized to receive 50 µg vitamin D3 (2000 IU) daily or matching placebo for 12 weeks. A bi-weekly questionnaire was used to record the incidence and severity of URI symptoms. There was no difference in the incidence of URIs between the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively, $P=0.57$). There was no difference in the duration or severity of URI symptoms between the vitamin D and placebo groups [5.4 ± 4.8 days vs. 5.3 ± 3.1 days, respectively, $P=0.86$ (95% CI for the difference in duration -1.8 to 2.1)]. The mean 25-hydroxyvitamin D level at baseline was similar in both groups (64.3 ± 25.4 nmol/l in the vitamin D group; 63.0 ± 25.8 nmol/l in the placebo group; n.s.). After 12 weeks, 25-hydroxyvitamin D levels increased significantly to 88.5 ± 23.2 nmol/l in the vitamin D group, whereas there was no change in vitamin D levels in the placebo group. There was no benefit of vitamin D3 supplementation in decreasing the incidence or severity of symptomatic URIs during winter. Further studies are needed to determine the role of vitamin D in infection.

Key words: Colds, influenza, URI, vitamin D.

INTRODUCTION

Vitamin D is produced in the skin when sunlight is absorbed. Thus, vitamin D levels, or serum 25-hydroxyvitamin D (25-OHD), fluctuate seasonally. 25-OHD levels are low during winter in northern latitudes because of decreased amounts of sunlight. A conventional diet usually does not provide adequate amounts of vitamin D. Vitamin D insufficiency results

in a number of skeletal and extra-skeletal complications when serum 25-OHD concentrations are <75 nmol/l. It has been associated with reduced calcium absorption, osteoporosis and increased fracture risk [1]. It has also been associated with decreased muscle strength [2], breast cancer [3, 4], colon cancer [5], cardiovascular disease [6], and autoimmune disorders such as rheumatoid arthritis [7] and systemic lupus erythematosus [8]. *In vitro* and *in vivo* studies show a role for vitamin D as an important component of the innate immune system. The innate immune system provides front-line protection against infectious agents. Expression of vitamin D receptor was

* Author for correspondence: J. F. Aloia, M.D., Winthrop University Hospital, 222 Station Plaza North, Suite 510, Mineola, NY 11501, USA.
(Email: jaloia@winthrop.org)

found in different cells of the myeloid and lymphoid lineage. The active form of vitamin D, 1,25-dihydroxy-vitamin D (1,25-OH₂D) increases the production of endogenous antibiotics called antimicrobial peptides (AMP) in human monocytes, neutrophils, and epithelial cells [9]. AMPs such as defensin and cathelicidin have a broad range of actions against microorganisms, including bacteria, fungi and viruses. Defensins can block viral infection by directly acting on the virion or by affecting the target cell and thereby indirectly interfering with viral infection [10]. One of the defensins called retrocyclin-2 inhibits influenza virus infection by blocking membrane fusion mediated by the viral haemagglutinin [11].

Liu *et al.* showed that stimulation of toll-like receptors (TLR) 2/1 engages a vitamin D-dependent intracellular circuit that results in the expression of cathelicidin, enhancing the microbicidal capability of the monocyte [12]. Markedly, these authors also observed that sera from African American individuals, who are known to have substantially lower serum 25-OHD levels than whites [13] were inefficient in inducing genetic expression of cathelicidin. When these authors supplemented the sera with 25-OHD, cathelicidin levels increased to levels observed in monocytes collected from whites. This suggests that vitamin D insufficiency during winter may be the 'seasonal stimulus' that increases susceptibility to infections, particularly viral respiratory infections including influenza virus, as first suggested by Hope-Simpson in 1987 [14] and 1992 [15].

It is estimated that 72% of adults experience at least one URI per year and those adults experience an average of 2.5 URIs per year [16]. Every year 5–20% of the USA population get influenza [17]. Vitamin D may also play a role in reducing the severity of URI symptoms by regulating specific cytokines that participate in the host inflammatory response. 1,25-OH₂D has been shown to inhibit mononuclear and T lymphocyte cell proliferation by decreasing the production of IL-1 β , IL-2, IL-6, interferon γ (IFN- γ), and TNF- α [18]. A randomized controlled trial by Schleithoff *et al.* showed that 50 μ g/day (2000 IU/day) vitamin D3 reduced the inflammatory milieu in congestive heart failure patients [19].

When reviewing the adverse events from our previous study of vitamin D3 supplementation in postmenopausal African American women [20] we noticed a significant difference in the reported incidence of URI symptoms between the vitamin D and placebo groups. In this 3-year randomized controlled trial, the

subjects received either placebo or 20 μ g/day vitamin D3. After 2 years, the vitamin D3 dose was increased to 50 μ g/day in the active group. There were 39 reports of URI symptoms: 30 in the placebo group vs. 9 in the vitamin D group ($P < 0.0002$). When we examined the seasonality of the symptoms, we found that the placebo group had URI symptoms mostly in winter. The vitamin D group had symptoms throughout the year while on 20 μ g/d, whereas only one subject had a URI while on 50 μ g/d. This finding led us to conclude that higher doses of vitamin D supplementation may protect against symptomatic URIs.

Current recommendations for vitamin D intake are based on the amounts required to sustain optimal skeletal health. Schleithoff *et al.*'s study and our previous study suggest that optimal function of the innate immune system might require higher doses of vitamin D. The current recommended intake of vitamin D for adults is 400 IU/day (10 μ g/day). In this study we administered 50 μ g/day (2000 IU) vitamin D3 which is the tolerable upper intake level of vitamin D for children and adults set by the Food and Nutrition Board of the Institute of Medicine [21]. Experts in the USA believe that higher intakes of vitamin D are necessary and that these higher intakes are safe [22, 23].

The aim of this study was to evaluate whether vitamin D3 supplementation of 50 μ g/day during the winter season prevents symptomatic URIs in adults, and whether vitamin D3 supplementation decreases the severity and duration of URI symptoms.

SUBJECTS AND METHODS

Subjects

Study participants were recruited from the Long Island, New York community (latitude, 40.7° N) between December 2006 and March 2007 (Fig. 1). Volunteers were recruited from local newspaper advertisements, mailing of brochures to community residents, and flyers posted at Winthrop University Hospital medical offices. Patients were eligible for the study if they met the following criteria: ambulatory adult age 18–80 years and stable medical condition with no change in medications for 6 months prior to study entry. Exclusion criteria included morbid obesity (body mass index > 35 kg/m²); current tobacco use; history of hypercalcaemia, nephrolithiasis or sarcoidosis; pregnancy; recent hospitalization; current liver or kidney disorders, malignancy and




Fig. 1. Flowchart of study participants.

malabsorption; and use of immunosuppressants or medications that interfere with vitamin D metabolism such as phenytoin and carbamazepine. Race determination was by self-declaration. All participants provided written informed consent and the trial was approved by the institutional review board of Winthrop University Hospital.

Study design

This study was a 3-month prospective, randomized, double-blind, placebo-controlled trial of vitamin D3 supplementation in ambulatory adults. Recruitment began in December 2006 to March 2007 and the study was completed in June 2007. The participants were randomly assigned using a computer-generated randomization sequence to receive either 50 µg/d vitamin D3 or matching placebo. Each subject was sequentially assigned a number upon study entry and the investigators dispensed the corresponding sequentially numbered container of study medication to the

subject. All participants and investigators were blinded throughout the study except for the research pharmacist and the statistician. Neither the statistician nor the research pharmacist had any contact with study participants. Dietary calcium and vitamin D intake was assessed using a food frequency questionnaire. Eligible subjects underwent a baseline medical history, height and weight measurements, and blood tests. Subjects were seen at 6 weeks and 12 weeks post-randomization. Blood was collected again at the 12-week visit.

URI assessment

A bi-weekly questionnaire (available in the online version of the paper) modified from established, validated instruments [24, 25] was used to record the incidence of URI symptoms in the subjects. The questionnaire inquired about symptoms of URI, duration and severity of symptoms, sick contacts, medication use, sick leave due to illness, and doctor

visits. The questionnaire was available online for subjects to complete. Subjects were emailed bi-weekly reminders to complete the questionnaire or they were mailed questionnaires bi-weekly if they preferred to receive them by mail. Subjects were called by phone if they did not answer a questionnaire after 4 weeks. URI was defined as the presence of two or more URI symptoms (fever, cough, productive sputum or change in sputum color and quantity, muscle aches, nausea or vomiting) and the absence of allergy symptoms (clear nasal discharge, watery eyes, and itchy nose).

Laboratory tests

Serum 25-OHD was measured by a radio-receptor assay from DiaSiorin Inc. (USA). The intra-assay variability in our laboratory is 4.1% and inter-assay variability is 7.0%. Our laboratory participates in the international Vitamin D External Quality Assessment Program (<http://www.deqas.org>). Serum parathyroid hormone (PTH) was measured by the Immulite 2000 Analyzer for the quantitative measurement of intact PTH (Diagnostic Products Corporation, CA). Vitamin D3 content was analysed in an independent laboratory (Vitamin D, Skin, and Bone Research Laboratory, Department of Medicine, Boston University School of Medicine, Boston, MA, USA).

Statistical analysis

To assess the effect of vitamin D supplementation on the incidence of URI, elementary χ^2 test, correlation, and *t* tests (both independent and paired) were used. Severity and duration of URIs were measured both across the overall sample of URI reports as well as stratified by patient. Mean severity and duration was calculated first with missing values set to zero (i.e. treating those who do not report a URI as having zero severity and duration) and then again with missing values ignored (i.e. calculating mean severity and duration only in those who actually report a URI). In the main analysis all data were used, but secondary analyses ignored the data for the first 4 weeks because it takes about 3 months for vitamin D levels to approach steady state [26]. As results under all combinations of the above scenarios did not differ, only results calculated within subjects who actually report a URI using all available data are reported. A mixed-model repeated-measures analysis of variance measured continuous change (e.g. severity of illness) over

time in the vitamin D group compared to the placebo group. An 'exchangeable' covariance structure was used in the repeated-measures analysis, i.e. the working correlation structure assumed a constant correlation between all time points. The General Linear Model (GenMod) was used to analyse the incidence of URIs in repeated measures on the same patient. Means were expressed as 95% confidence intervals when appropriate. $P < 0.05$ was the nominal definition of statistical significance. All analyses were carried out using SAS version 9.1 (SAS Institute Inc., USA).

RESULTS

Baseline characteristics

The baseline characteristics and laboratory values of the study population are summarized in Table 1. There were no significant differences between the active and placebo patients at baseline. The baseline 25-OHD levels ranged from 16 to 156 nmol/l with a mean level of 63.7 ± 28.7 nmol/l in the study population. At baseline, 23% of the active patients exceeded 75 nmol/l.

Adherence

Adherence (defined as the ratio of the number of pills consumed to the number of days in the study) ranged from 59% to 100%. Mean compliance was $94 \pm 9\%$. Adherence did not significantly differ between the active and placebo groups. Fourteen patients discontinued the study (Fig. 1). Twelve of the 14 patients discontinued by week 6 of the study. The other two discontinued at week 8 of the study.

Incidence of URIs

A total of 751 questionnaires were returned by the participants. Each participant returned an average of five questionnaires during the 12-week study. There was no difference in the incidence of URIs between the vitamin D and placebo groups. There were 48 URIs out of 388 reports in the vitamin D group and 50 URIs out of 363 reports in the placebo group. This difference of 1.4% in favour of vitamin D (95% CI -2.4 to 3.4) was not statistically different ($P = 0.56$). There was also no observed difference in the number of subjects who had at least one URI between the vitamin D group (28 patients, 36%) and the placebo

Table 1. *Baseline characteristics of study participants. There were no significant differences between the study groups at baseline*

Characteristic	Active (n=78)	Placebo (n=70)
Age, years (mean \pm s.d.)	59.3 \pm 13.0	58.1 \pm 13.4
BMI (kg/m ²)	26.1 \pm 4.5	26.6 \pm 4.1
Male, n (%)	17 (21.8%)	13 (18.6%)
Female, n (%)	61 (78.2%)	57 (81.4%)
Race, n (%)		
Caucasian	70 (89.7%)	61 (87.1%)
African American	3 (3.8%)	3 (4.3%)
Asian	2 (2.6%)	6 (8.6%)
Other	3 (3.8%)	0 (0.0%)
25-OHD (nmol/l) (mean \pm s.d.)	64.3 \pm 25.4	63.0 \pm 25.8
PTH (pg/ml)	29.2 \pm 13.6	28.4 \pm 12.6
History of tobacco use, n (%)	26 (33.3%)	28 (40%)
History of asthma, n (%)	6 (7.7%)	2 (2.9%)
History of COPD, n (%)	3 (3.8%)	2 (2.9%)
Received influenza vaccine, n (%)	44 (56.4%)	45 (64.3%)
Dietary calcium intake (mg/d)	762.8 \pm 375.7	854.6 \pm 518.6
Dietary vitamin D intake (IU/d)	147.3 \pm 182.3	168 \pm 146.5

BMI, Body mass index; PTH, parathyroid hormone; COPD, chronic obstructive pulmonary disease.

group (29 patients, 41%). The 5% difference in URI incidence rate (95% CI -12 to 20) in favour of the vitamin D group was not statistically different ($P=0.74$). A GenMod analysis, accounting for the clustering of URIs within patients, did not reveal any differences in respect of URI incidence in the two groups ($P=0.61$). We also analysed the results after excluding the first 4 (and 2 and 6) weeks of questionnaires, considering that it takes 3 months for vitamin D levels to increase, and found no difference in the incidence of URIs between the treatment and placebo groups.

Severity and duration of URIs

There was no difference in the duration of URIs between the vitamin D and placebo groups (95% CI for the difference in duration -1.8 to 2.1) (Table 2). There was also no difference in the severity of URIs between the two groups. Participants rated the severity of their symptoms on a 5-point scale (1=healthy, 5='very ill'). There was no statistically significant linear relationship (correlation coefficient) between 25-OHD levels and the number of URIs, the number of symptoms, the severity of symptoms or the duration of the URI. There was no difference in the frequency of URI symptoms between active and placebo patients except for muscle aches: 2% of active patients complained of

muscle aches compared to 6% of placebo patients ($P<0.01$).

Laboratory values

Blood samples were collected from a large subset of patients (150/162 patients, 92.6%). 25-OHD levels (expressed as nmol/l) increased in the vitamin D group from a mean of 64.3 \pm 25.4 to 88.5 \pm 23.2. This difference of 24 nmol/l (95% CI 21.7-30.8) was statistically significant compared to the change in the placebo group which had a mean change of -2.1 nmol/l (95% CI -7.1 to 2.8, $P<0.0001$). At the end of the study, 73% of the active patients exceeded 75 nmol/l. Serum calcium levels remained the same in both groups (9.3 mg/dl at the beginning and end of study).

Adverse events

A total of 72 adverse events were reported in the study over 3 months, 38 in the vitamin D group and 34 in the placebo group ($P=0.99$) (Table 3). There was no significant difference in the adverse events between the study groups. There were three serious adverse events, one in the vitamin D group and two in the placebo group. One patient in the vitamin D group had chest pain requiring hospitalization with no evidence of

Table 2. Characteristics of URIs by group

	Vitamin D (<i>n</i> = 78)	Placebo (<i>n</i> = 70)	<i>P</i> value
Reported URI (<i>n</i>)	28 (36%)	29 (41%)	0.61
Duration of URI, days (mean ± s.d.)	5.4 ± 4.8	5.3 ± 3.1	0.86
Severity of URI, range 1–5 (mean ± s.d.) (1 = healthy; 5 = very ill)	2.6 ± 1.0	2.8 ± 1.2	0.4

URI, upper respiratory tract infection.

Table 3. Adverse events

	Vitamin D (<i>n</i> = 78)	Placebo (<i>n</i> = 70)
Gastrointestinal discomfort		
Constipation	1	0
Diarrhoea	5	2
Gastritis	1	3
Gallstones	0	1
Musculoskeletal symptoms		
Joint pain	2	4
Myalgias	2	1
Back pain	1	0
Chest pain	1	2
Palpitations	1	0
Infections		
Pneumonia	0	1
Urinary tract infection	3	1
Sinus infection	5	1
Herpes zoster (shingles)	0	2
Oral candidiasis	0	1
Tooth infection	0	1
Conjunctivitis	0	1
Headache	2	0
Dizziness	1	0
Allergic rhinitis	10	6
Falls	0	2
Fatigue	2	1
Skin changes		
Dry skin	1	0
Hair thinning	0	1
Brittle nails	0	3
Total	38	34

myocardial infarction. One patient in the placebo group was hospitalized with high fever and chills with no evidence of bacterial infection. Another patient in the placebo group broke an ankle after a fall. None of the serious adverse events were considered to be related to the study medication. There were no episodes of nephrolithiasis or hypercalcaemia.

DISCUSSION

This is the first randomized, double-blind, placebo-controlled trial of vitamin D3 supplementation for URI prevention that we are aware of. We found no benefit of vitamin D3 supplementation in decreasing the incidence or severity of URIs during the winter months. Our results differed from Laaksi *et al.* who found that low 25-OHD levels in young Finnish men were associated with more absences due to respiratory infection (incidence rate ratio 1.63, 95% CI 1.15–2.24) [27]. A sub-study analysis of the RECORD (Randomised Evaluation of Calcium and/OR vitamin D) trial showed a trend towards lower rates of infection in the vitamin D group, but the results were not statistically significant [28]. Of note, the RECORD trial used a lower dose of vitamin D3, i.e. 20 µg/day.

Mild URIs occurring during the winter months are most often due to viruses, e.g. respiratory syncytial virus (RSV). During late winter/early spring, the influenza season begins. Influenza runs the clinical spectrum of mild disease, resembling RSV, to fulminant/fatal influenza pneumonia. Influenza A is more severe than influenza B and affects adults more commonly than children. Mild influenza A is clinically indistinguishable from influenza B and can only be differentiated by specific diagnostic testing serologically or by antibody testing and sputum or in respiratory secretion specimens. Influenza-like illness (ILI) is a symptomatic definition and can include both RSV and influenza infections, as well as other viral infections that cause fever, nausea, myalgia, and/or cough. The 2006–2007 influenza season in Long Island, NY matched patterns in the mid-Atlantic region where levels of influenza activity increased during January, peaked in early March, and decreased in May [29, 30].

There are several reasons why vitamin D3 supplementation may have been ineffective at preventing URIs in this study. First, the subjects started vitamin D3 supplementation during the wintertime and not

beforehand. It takes about 3 months for 25-OHD levels to reach a steady state with supplementation [26, 31]. Because it takes a significant amount of time to build up vitamin D stores, the effect of vitamin D supplementation lagged behind the cold and influenza season. Vitamin D3 supplementation may be more effective in preventing URIs if started during autumn when sunlight begins to decrease. Another reason why we may not have observed a benefit is that 50 µg/day may not be enough to stimulate innate immunity, although in our previous study this dose led to decreased reports of wintertime URIs in African American women. African Americans are known to have lower vitamin D levels because of darker skin pigmentation [13]. The subjects in our previous study started with a lower baseline 25-OHD level of 46.9 ± 20.6 nmol/l (95% CI 43.9–50.39) when compared to the baseline level of the subjects in this study (63.7 ± 28.7 nmol/l) but they reached similar 25-OHD levels of 86.9 ± 27.0 nmol/l (95% CI 80.1–94.1, $P < 0.001$) after being on 50 µg vitamin D3 daily for 3 months [20]. Lower vitamin D levels, as shown in Liu *et al.*'s study [12], were associated with decreased cathelicidin expression, thus vitamin D supplementation may have a greater benefit in subjects with lower baseline vitamin D levels. In this study, only 4% of the study participants were African American. The effect of vitamin D3 supplementation on URI prevention may not be as pronounced in this study population consisting mostly of Caucasians because the baseline 25-OHD levels were higher.

The strengths of the present study include the high compliance rate of medication intake (94%) and low dropout rate. We also used an objective definition of URI to include two or more symptoms in the absence of allergy symptoms. We had high cooperation in return of surveys because most of the subjects completed the questionnaires online. Thus, we had real-time collection of data which decreases recall bias since the time interval between each survey was only 2 weeks. The mean 25-OHD level of the subjects at baseline (63.7 ± 28.7 nmol/l) was in accord with the mean 25-OHD level in NHANES III (64.8 nmol/l) measured during winter [32]. Our laboratory participates in the international Vitamin D External Quality Assessment Program which ensures the analytical reliability of 25-OHD assays. Vitamin D content in the tablets was verified by an independent laboratory. We also used vitamin D3 instead of vitamin D2 which some believe increases 25-hydroxyvitamin D levels more effectively than vitamin D2 [33, 34].

We recognize the following limitations of this study. First, the subjects were not on vitamin D before the influenza season began. As mentioned previously, the effect of vitamin D supplementation on the immune system may be more evident with higher vitamin D levels achieved at the beginning of the influenza season. Second, the mean 25-OHD level at the beginning of the study was not that low and was similar to the level seen in NHANES III. Seventy-three per cent of patients in the vitamin D group achieved 25-OHD levels >75 nmol/l but the difference between baseline and end-of-study levels may not be enough to confer a benefit. Third, the study was powered initially to detect a 25% difference in the incidence of URIs in the placebo group *vs.* the vitamin D group. The literature suggested that 72% of adults have at least one URI every year. To be conservative we assumed that the incidence of URIs in the placebo *vs.* vitamin D groups would be 55% *vs.* 30%, respectively, and calculated that a sample of 85 patients in each group would allow us to observe statistical differences with 92% power. We assumed a 12-week attrition rate of 15%, so that the recruitment target was 100 patients in the active and placebo groups. Although we did not meet our enrolment goals, we still had 80% power to detect a 23% difference in the incidence of URIs between the vitamin D and placebo patients. However, because the two groups were actually very close, the more relevant measure is the 95% confidence interval for the difference in incidence rates. That interval is -12% to 20% . One can interpret from our results (at 50 µg/day) that we are 95% confident that vitamin D did not decrease the incidence of URIs by $>20\%$. If a smaller difference between active and placebo is chosen to be detected (i.e. $<20\%$), a study with a larger sample size and/or a greater dose would be required. Another factor that could have diminished the difference between the vitamin D and placebo groups is the high influenza vaccination rate in both groups (56.4% of subjects in vitamin D group, 64.3% in placebo group). This indicates a relatively health-conscious population. Vaccination could have decreased the overall incidence of symptomatic URI, thus reducing the power.

Although the present study did not show a benefit of vitamin D3 supplementation in preventing viral URIs, there is accumulating evidence that vitamin D does significantly alter the immune system. Because this study was conducted in ambulatory patients, patients with mild URIs probably had colds due

to various viruses. The host defence that prevents intracellular viral replication is cell-mediated immunity (CMI) by T lymphocytes. Vitamin D may enhance CMI which may be effective in severe/hospitalized cases of influenza. Since months are required for vitamin D levels to achieve peak/steady-state concentrations, further studies should be done giving vitamin D during autumn, before the influenza season and specifically study severe/hospitalized patients with influenza to determine if vitamin D has a salutary effect on this patient subset.

NOTE

Supplementary material accompanies this paper on the Journal's website (<http://journals.cambridge.org/hyg>).

ACKNOWLEDGEMENTS

This research was partially funded by the Empire Clinical Research Investigator Program (ECRIP). We thank Tatiana Baron, D.O., Cindy Bredefeld, D.O., Lawrence Eisenstein, M.D., Sara Nausheen, M.D. and Uzma Syed, D.O. for their clinical care and data gathering. We thank Jane Greensher for her expertise as the Nurse Coordinator, and Marty Feuerman for contributing to the data and statistical analyses.

DECLARATION OF INTEREST

None.

REFERENCES

1. **Heaney RP.** Functional indices of vitamin D status and ramifications of vitamin D deficiency. *American Journal of Clinical Nutrition* 2004; **80**: 1706S–1709S.
2. **Visser M, Deeg DJ, Lips P.** Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. *Journal of Clinical Endocrinology and Metabolism* 2003; **88**: 5766–5772.
3. **Bertone-Johnson ER, et al.** Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. *Cancer Epidemiology Biomarkers & Prevention* 2005; **14**: 1991–1997.
4. **Lappe JM, et al.** Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *American Journal of Clinical Nutrition* 2007; **85**: 1586–1591.
5. **Freedman DM, Dosemeci M, McGlynn K.** Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. *Occupational & Environmental Medicine* 2002; **59**: 257–262.
6. **Schmidt-Gayk H, et al.** Serum 25-hydroxycalciferol in myocardial infarction. *Atherosclerosis* 1977; **26**: 55–58.
7. **Cutolo M, et al.** Vitamin D in rheumatoid arthritis. *Autoimmunity Reviews* 2007; **7**: 59–64.
8. **Cutolo M, Otsa K.** Vitamin D, immunity and lupus [Review]. *Lupus* 2008; **17**: 6–10.
9. **Wang TT, et al.** Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *Journal of Immunology* 2004; **173**: 2909–2912.
10. **Klotman ME, Chang TL.** Defensins in innate antiviral immunity. *Nature Reviews Immunology* 2006; **6**: 447–456.
11. **Leikina E, et al.** Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. *Nature Immunology* 2005; **6**: 995–1001.
12. **Liu PT, et al.** Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* 2006; **311**: 1770–1773.
13. **Harris SS, Dawson-Hughes B.** Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. *American Journal of Clinical Nutrition* 1998; **67**: 1232–1236.
14. **Hope-Simpson RE, Golubev DB.** A new concept of the epidemic process of influenza A virus. *Epidemiology and Infection* 1987; **99**: 5–54.
15. **Hope-Simpson RE.** *The Transmission of Epidemic Influenza*. New York: Plenum Press, 1992.
16. **Fendrick AM, et al.** The economic burden of non-influenza-related viral respiratory tract infection in the United States. *Archives of Internal Medicine* 2003; **163**: 487–494.
17. **Centers for Disease Control and Prevention.** Key facts about influenza and influenza vaccine (<http://www.cdc.gov/flu/keyfacts.htm>). Accessed 1 February 2008.
18. **Lemire JM.** Immunomodulatory role of 1,25-dihydroxyvitamin D3. *Journal of Cell Biochemistry* 1992; **49**: 26–31.
19. **Schleithoff SS, et al.** Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. *American Journal of Clinical Nutrition* 2006; **83**: 754–759.
20. **Aloia JF, et al.** A randomized controlled trial of vitamin D3 supplementation in African American women. *Archives of Internal Medicine* 2005; **165**: 1618–1623.
21. **Institute of Medicine, Food and Nutrition Board.** *1999 Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride*. Washington, DC: National Academy Press.
22. **Heaney RP, et al.** Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *American Journal of Clinical Nutrition* 2003; **77**: 204–210.

23. **Vieth R, et al.** The urgent need to recommend an intake of vitamin D that is effective. *American Journal of Clinical Nutrition* 2007; **85**: 649–650.
24. **Chubak J, et al.** Moderate-intensity exercise reduces the incidence of colds among postmenopausal women. *American Journal of Medicine* 2006; **119**: 937–942.
25. **Nieman DC, et al.** Physical activity and immune function in elderly women. *Medicine & Science in Sports & Exercise* 1993; **25**: 823–831.
26. **Vieth R, Chan PC, MacFarlane GD.** Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. *American Journal of Clinical Nutrition* 2001; **73**: 288–294.
27. **Laaksi I, et al.** An association of serum vitamin D concentrations <40 nmol/l with acute respiratory tract infection in young Finnish men. *American Journal of Clinical Nutrition* 2007; **86**: 714–717.
28. **Avenell A, et al.** Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people [RECORD trial, ISRCTN 51647438]. *Age and Ageing* 2007; **36**: 574–577.
29. **New York State Department of Health.** (<http://www.health.state.ny.us/diseases/communicable/influenza/surveillance.htm>). Accessed 1 February 2008.
30. **Centers for Disease Control and Prevention.** 2006–07 U.S. influenza season summary (<http://www.cdc.gov/flu/weekly/weeklyarchives2006-2007/06-07summary.htm>). Accessed 1 February 2008.
31. **Barger-Lux MJ, et al.** Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. *Osteoporosis International* 1998; **8**: 222–230.
32. **Looker AC, et al.** Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone* 2002; **30**: 771–777.
33. **Trang HM, et al.** Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. *American Journal of Clinical Nutrition* 1998; **68**: 854–858.
34. **Houghton LA, Vieth R.** The case against ergocalciferol (vitamin D2) as a vitamin supplement. *American Journal of Clinical Nutrition* 2006; **84**: 694–697.